Oppenheimer Downgrades Legend Biotech to Perform, Lowers Price Target to $40

Benzinga Newsdesk www.benzinga.com Negative 83.8%

Neg 83.8% Neu 0% Pos 0%

Oppenheimer analyst Trevor Allred downgrades Legend Biotech (NASDAQ:LEGN) from Outperform to Perform and lowers the price target from $75 to $40.